Q2 2026 saw 18% revenue growth, robust backlog, and raised guidance for revenue, EBITDA, and EPS. Strategic moves included the $800M medical business sale and PCG acquisition, sharpening focus on core nuclear markets and expanding U.S. manufacturing.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.